Back to catalogue
№ 308 34 filings · 2021-09-27 → 2026-07-24

RENISHAW PLC

RSW
Industrial Goods and Services Share price 5,010p Market cap £3.7bn Overall fit 665 /1000

Genuine AI-receiver via encoder sales to semiconductor manufacturing equipment builders, with strongly-evidenced operating leverage and fortress balance sheet, but the shares have re-rated 74% in 12 months and now sit at ~27-29x forward earnings — fair-to-full valuation limits it to the 'strong buy with reservations' band rather than the top tier.

Fair value range 4,500p–5,600p Mid case · £3.7bn
Absolute upside -1.1% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Operating leverage already visible in H1 FY2026 numbers (49.6% constant-FX profit growth on 11.5% revenue)
  • Multiple valuation methods converge around current price
  • Consistent, granular disclosure across 5 years of filings; two FY2026 guidance raises both delivered
Limits the call
  • Semiconductor capex cycle is genuinely hard to time; a rollover would compress revenue and multiple simultaneously
  • Governance in transition (Chair, CFO, new NED all being recruited; founder death Dec 2024)
Methodology

Forward P/E on FY2026-27 adjusted EPS cross-checked against operating-margin normalisation

In one line · bull case

Genuine picks-and-shovels AI/semi-capex beneficiary via precision encoders sold into semiconductor manufacturing equipment, with visible operating leverage and fortress balance sheet — but the shares have already re-rated 74% and sit near the top of a fair-value range.

In one line · biggest risk

Semiconductor capex cycle turning down would simultaneously compress revenue growth and the earnings multiple, undoing much of the FY2026 re-rating.

Drivers
AI beneficiary 72 /100
Position Measurement encoders and calibration systems are directly bought by semiconductor equipment builders; explicitly cited as key growth driver in three FY2026 filings.
Operating leverage 75 /100
H1 FY2026 delivered 49.6% constant-FX operating profit growth on 11.5% revenue growth; fixed-cost UK-heavy manufacturing base with completed capacity expansion.
Earnings vs expectations 72 /100
Two upward guidance revisions during FY2026, both delivered at or above upgraded ranges; FY2025 also at top of range.
Growth momentum 77 /100
Revenue accelerating from +3% FY2025 to +14% FY2026 guided; Q4 FY2026 +27% YoY; PBT +31% YoY.
Moat 68 /100
Deep patent portfolio, high switching costs (encoders designed into customer machines), specialist niche leadership over 50+ years.
Earnings quality 72 /100
Clear disclosure of adjusting items (restructuring, one-off tax, pension); 91% cash conversion in FY2025.
Management quality 62 /100
Long-tenured but founder passed away Dec 2024; Chair, CFO and additional NED being recruited — governance in transition.
Cyclicality 65 /100
Serves semi capital equipment, machine tools, aerospace, automotive, consumer electronics — moderately-to-highly cyclical.
Leverage 8 /100
£240.9m net cash at H1 FY2026, no meaningful debt — fortress balance sheet.

RENISHAW PLC (RSW) — Investment Research Note

Executive summary

Renishaw is a UK-based world leader in precision measurement and manufacturing systems, with three segments — Industrial Metrology, Position Measurement (encoders), and Specialised Technologies (additive manufacturing and spectroscopy) — sold globally to industrial machine builders and semiconductor equipment OEMs. Across the filings the company has emerged from a challenging FY2023–FY2025 (revenue flat around £690–£713m, ~15–16% adjusted operating margin) into a sharply accelerating FY2026, with revenue guided to ~£815m (+14%), adjusted PBT ~£167m (+31%), record Q4 of £243m (+27%), and semiconductor/electronics and aerospace/defence as the identified demand drivers 2026-07-24 trading statement; 2026-05-06 Q3 update; 2026-02-11 H1 results. The single most important point for valuation today: the share price has re-rated 74% over the last twelve months into the semi/AI-capex upcycle, and now trades at ~27–29x FY2026 adjusted EPS — the operating leverage story is real, but the price already discounts a good portion of it.

Fair value estimate

  • Fair value range: 4,500p – 5,600p per share; implied market cap ~£3,275m – £4,075m; midpoint ~£3,675m.
  • Methodology: forward earnings multiple, cross-checked against operating-margin normalisation. FY2026 adjusted PBT ~£167m at ~22% tax = ~£130m net income → 179p EPS. Applying 25–31x forward P/E (justified by high-single-digit through-cycle organic growth target, 20% target operating margin, fortress balance sheet, and semi-capex exposure) gives 4,475p–5,555p. A more optimistic FY2027 scenario (£900m revenue at 20% adjusted op margin, ~£190m PBT, EPS ~204p, 27x P/E) supports up to ~5,500p.
  • Current market cap £3,785.8m; current price 5,205p — sits just above the midpoint of our range.
  • Absolute upside/downside: roughly –3% to +8% vs midpoint; range of –14% to +8% vs current price. Broadly fair.

Sector context

  • Sector classification is confirmed: Industrial Goods & Services (ICB).
  • Quality profile is above typical sector peers: fortress balance sheet (net cash £241m at Dec-25), very high in-house R&D content (12%+ of revenue), specialised precision products with high switching costs. Growth is above peers in the current cycle due to semi-capex tailwind; leverage is materially below peers (net cash vs typical 1–2x net debt).
  • Listed peers: Spectris (LON: SXS), Halma (LON: HLMA), IMI (LON: IMI). International: Keyence (JP) on precision sensing.

Investment thesis (3 bullets)

  1. Genuine AI/semi-capex beneficiary via precision encoders and machine calibration. Position Measurement grew +21.6% constant-FX in 9M FY2026 driven by "very strong sales growth for open optical and magnetic encoders … from the semiconductor and electronics manufacturing equipment sector," with the order book expanding 2026-05-06 Q3 update. These encoders sit inside the lithography/wafer-handling equipment that fabs are buying to make AI chips — a direct picks-and-shovels linkage.
  2. Meaningful operating leverage is now visible in reported numbers. H1 FY2026 delivered adjusted operating profit +49.6% at constant FX on only +11.5% constant-FX revenue growth, with 4.4pp of organic margin improvement from fixed-cost reduction, productivity and operating leverage 2026-02-11 half-year report. Target is 20% adjusted operating margin vs FY2026 running rate ~18.6%; even a small further step-up compounds materially in EPS.
  3. Fortress balance sheet + founder-family long-term commitment. £240.9m cash and deposits at H1 FY2026, no meaningful debt, and the McMurtry/Deer families reaffirmed long-term commitment via formation of Deltam Holdings (50.25% stake) in Nov 2025 2026-02-11 half-year report. This removes both refinancing risk and any repeat of the 2021 formal sale process overhang.

Key risks (3 bullets)

  1. Cyclicality of semiconductor capex. The current growth surge is driven by a specific spending cycle; FY2023–H1 FY2026 showed how quickly demand from this sector can soften (encoders were the weak point earlier in the period) 2025-09-18 FY2025 final results. A capex pause would compress the operating leverage that is currently working in the company's favour.
  2. Governance concentration and management transition. Founder Sir David McMurtry died in Dec 2024; Deltam Holdings owns 50.25%; the Board is still recruiting an independent Non-executive Chair and a permanent CFO (Allen Roberts retired Dec 2025, replaced by an interim finance director) 2026-02-11 half-year report; 2025-08-21 Board change. Founder-controlled structure limits ability of external shareholders to influence decisions.
  3. FX and tariff exposure. ~20% of revenue is USD-denominated with UK-heavy manufacturing base; H1 FY2026 saw 3.6pp of margin headwind from currency, and US tariffs added new cost lines partially offset by pricing 2026-02-11 half-year report. Further GBP strength or unresolved tariff regime would erode margins directly.

Operating leverage

Renishaw is a classic high-fixed-cost UK-based industrial with strong incremental leverage, and the FY2026 numbers make this quantifiable. On the H1 FY2026 income statement, gross margin (ex-engineering) was 58.8% of revenue 2026-02-11 half-year report. Group headcount was cut ~7% from 5,347 to 4,975 during H1 FY2026, delivering ~£23m of annualised cost savings via the recently completed £20m redundancy programme. R&D and central overheads are largely fixed. The Miskin (Wales) facility expansion has already been built, giving spare capacity. The result is that incremental revenue drops through at very high contribution margins: H1 FY2026 saw 4.4pp of organic margin lift from a mix of fixed-cost reduction, productivity, and operating leverage on constant-FX growth of 11.5%. Adjusted operating profit at constant FX was +49.6% year-on-year on H1 revenue up 11.5% — an implied incremental operating margin north of 30% on the marginal revenue. If FY2027 revenue reaches £900m (+10% on FY2026) and the company hits its 20% adjusted operating margin target, adjusted operating profit rises from ~£152m to ~£180m (+18%); if the mix drives margin to 22%, operating profit reaches ~£198m (+30%). This is the "long-tail of upside" the portfolio brief describes. Cited: 2026-02-11 half-year report; 2025-09-18 FY2025 final results.

Value-trap signals

None identified — revenue is accelerating, order book is expanding across all three segments, dividend is progressive (78.1p FY2025, 2.5% raise), balance sheet has £241m cash with no meaningful debt, and management guidance has been repeatedly upgraded through FY2026 rather than missed.

Earnings vs. expectations

Across the filings the pattern is beats and progressive upgrades in FY2026, after in-line-to-soft FY2023–FY2025:

  • H1 FY2025 (Feb 2025): "steady progress in mixed trading conditions"; FY2025 guidance £695–735m revenue, £105–135m adjusted PBT.
  • Q3 FY2025 (May 2025): guidance narrowed to £700–720m revenue, £109–127m adjusted PBT.
  • Aug 2025 pre-close: adjusted PBT expected "towards the top" of £109–127m range — implicit beat vs midpoint.
  • FY2025 result (Sep 2025): adjusted PBT £127.2m — top of guided range.
  • H1 FY2026 (Feb 2026): FY2026 guidance £740–780m revenue, £132–157m adjusted PBT.
  • April 2026 trading update: upgraded to £775–805m and £145–165m — explicit guidance raise.
  • Q3 FY2026 (May 2026): performance in line with recently upgraded guidance.
  • July 2026 post-close: revenue ~£815m (above upgraded range) and adjusted PBT ~£167m (above upgraded range) — beat on both.

Pattern: consistent beats in FY2026, with two upgrades during the year. Suggests conservative guidance and genuine positive operating momentum.

Conviction

Conviction: 4 — high. Anchoring factors: (i) clean, consistent disclosure across five years of RNS filings with detailed segment and geographic breakdowns; (ii) the operating leverage thesis is not speculative — it is already visible in H1 FY2026 numbers (49.6% constant-FX profit growth on 11.5% revenue); (iii) multiple valuation approaches (forward P/E, margin normalisation, EV/revenue) converge around the current price band. Limiting factors: (a) semiconductor capex cycle timing is genuinely hard to predict, and a rollover would compress both revenue and multiple simultaneously; (b) founder-family control and ongoing chair/CFO search introduces some governance uncertainty.

Driver scoring (0-100)

  • ai_beneficiary (72): Position Measurement encoders are directly bought by semi equipment builders; management explicitly attributes accelerating growth to "the semiconductor and electronics manufacturing equipment sector" in three separate FY2026 filings. Also sells calibration systems to semi equipment builders. This is a real revenue linkage, not a marketing claim.
  • operating_leverage (75): Very high — H1 FY2026 delivered 49.6% constant-FX operating profit growth on 11.5% revenue growth, with fixed-cost UK-heavy manufacturing base and completed capex programme providing capacity.
  • earnings_surprise_trend (72): Two guidance raises during FY2026, both delivered on or ahead of upgraded ranges. FY2025 also delivered at top end of range.
  • cyclicality (65): Serves semi capital equipment, machine tools, aerospace, automotive, consumer electronics — moderately-to-highly cyclical, and the current tailwind is a cycle upswing.
  • moat (68): Deep patent portfolio in precision measurement, high switching costs (encoders are designed into customer machines), 50+ year specialist heritage, dominant position in specific niches.
  • leverage (8): Net cash £241m, no meaningful debt — fortress balance sheet.
  • earnings_quality (72): Adjusting items are disclosed and mostly relate to one-off restructuring, historical tax matters, and pension items. Cash conversion targeted at 70%+, achieved 91% in FY2025. Generally clean.
  • management_quality (62): Long-tenured, founder-influenced. Sir David McMurtry passed away Dec 2024; ongoing recruitment of independent Chair, new CFO, and additional NEDs suggests governance is in transition. Track record of capital allocation is solid but shareholder engagement historically limited.
  • growth_momentum (77): Revenue accelerating from -1% (FY2023) to +0.4% (FY2024) to +3.1% (FY2025) to +14% (FY2026); Q4 FY2026 was +27% YoY; PBT +31% YoY.

overall_score: 665

Renishaw fits the AI-receiver + operating-leverage thesis well: it is a genuine picks-and-shovels beneficiary of semiconductor capex (Position Measurement segment growth is explicitly semi-driven), has strongly visible operating leverage (H1 FY2026 constant-FX profit +49.6% on revenue +11.5%), and carries fortress-quality downside protection (£241m net cash, no debt, semi-recurring revenue base). The reservations are that the shares have already re-rated 74% in twelve months and now sit at 27–29x forward earnings, meaning the valuation is fair-to-full rather than cheap; incremental upside from here requires management to actually hit the 20% operating margin target. This places it clearly above "partial fit" (400–599) but not into the "genuinely cheap on AI-receiver thesis" top band. Score anchored in the 600–799 "strong buy with reservations" band, near the middle.

Filings consulted · 38

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-24Trading Statement2026-07-24_9685234_trading-statement.md0.85
  2. 2026-06-16Capital Markets Day2026-06-16_9619650_capital-markets-day.md0.95
  3. 2026-05-06Trading Statement2026-05-06_9553606_trading-statement.md0.85
  4. 2026-04-20Trading Statement2026-04-20_9526927_trading-statement.md0.85
  5. 2026-02-11Half Year Financial Report2026-02-11_9424652_half-year-financial-report.md0.90
  6. 2026-01-29Notice OF Half Year Results2026-01-29_9394037_notice-of-half-year-results.md0.90
  7. 2025-11-26Result OF Agm2025-11-26_9259102_result-of-agm.md0.26
  8. 2025-10-23Trading Statement2025-10-23_9188562_trading-statement.md0.72
  9. 2025-09-18Final Results2025-09-18_9115235_final-results.md0.85
  10. 2025-08-21Board Change And Trading Update2025-08-21_9066729_board-change-and-trading-update.md0.72
  11. 2025-06-17Capital Markets Day2025-06-17_8932414_capital-markets-day.md0.62
  12. 2025-05-08Trading Statement2025-05-08_8866470_trading-statement.md0.55
  13. 2025-02-13Half Year Report2025-02-13_8734514_half-year-report.md0.58
  14. 2024-11-27Result OF Agm2024-11-27_8576424_result-of-agm.md0.20
  15. 2024-10-24Trading Statement2024-10-24_8505246_trading-statement.md0.55
  16. 2024-09-12Final Results2024-09-12_8412429_final-results.md0.65
  17. 2024-05-08Trading Statement2024-05-08_8180880_trading-statement.md0.38
  18. 2024-02-06Half Year Report2024-02-06_8022988_half-year-report.md0.41
  19. 2024-01-23Notice OF Half Year Results2024-01-23_8002119_notice-of-half-year-results.md0.41
  20. 2023-11-29Result OF Agm2023-11-29_7910744_result-of-agm.md0.14
  21. 2023-10-26Trading Statement2023-10-26_7839870_trading-statement.md0.38
  22. 2023-10-13Notice OF Agm2023-10-13_7814110_notice-of-agm.md0.14
  23. 2023-09-19Final Results2023-09-19_7763278_final-results.md0.45
  24. 2023-04-28Trading Statement2023-04-28_7388_trading-statement.md0.21
  25. 2023-02-02Half Year Report2023-02-02_7352617_half-year-report.md0.23
  26. 2023-01-24Notice OF Half Year Results2023-01-24_7155564_notice-of-half-year-results.md0.23
  27. 2022-11-30Result OF Agm2022-11-30_7264520_result-of-agm.md0.07
  28. 2022-10-31Notice OF Agm2022-10-31_7208162_notice-of-agm.md0.07
  29. 2022-10-27Trading Statement2022-10-27_7160800_trading-statement.md0.21
  30. 2022-09-15Final Results2022-09-15_7316251_final-results.md0.25
  31. 2022-05-10Trading Statement2022-05-10_7240798_trading-statement.md0.21
  32. 2022-02-03Half Year Report2022-02-03_6707765_half-year-report.md0.23
  33. 2022-01-17Notice OF Half Year Results2022-01-17_6858133_notice-of-half-year-results.md0.23
  34. 2021-11-24Result OF Agm2021-11-24_6591043_result-of-agm.md0.07
  35. 2021-10-21Trading Statement2021-10-21_6522486_trading-statement.md0.21
  36. 2021-10-21Final Results Replacement2021-10-21_6523633_final-results-replacement.md0.25
  37. 2021-10-21Final Results2021-10-21_6522537_final-results.md0.25
  38. 2021-09-27Final Results Revised Date And Trading Update2021-09-27_6591719_final-results-revised-date-and-trading-update.md0.25

This research note was authored by a large language model after reading 34 regulatory filings published between 2021-09-27 and 2026-07-24. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.